Investor Overview Press Releases March 27, 2026 Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 March 20, 2026 Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting March 18, 2026 Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis View all » Events Mar 10, 20261:40 PM EDT Leerink Global Healthcare Conference Feb 26, 20268:40 AM EST Oppenheimer 36th Annual Healthcare Life Sciences Conference Feb 12, 20262:30 PM EST Guggenheim Emerging Outlook: Biotech Summit 2026 View all » Feature Presentation March 2026 Corporate Overview
March 27, 2026 Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
March 20, 2026 Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 18, 2026 Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
